Yatharth Hospit.

  • Market Cap: Small Cap
  • Industry: Hospital
  • ISIN: INE0JO301016
  • NSEID: YATHARTH
  • BSEID: 543950
INR
829.80
-0.25 (-0.03%)
BSENSE

Jun 11, 12:26 PM

BSE+NSE Vol: 64.25 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

64.25 k (-55.45%) Volume

Shareholding (Mar 2026)

FII

5.25%

Held by 58 FIIs

DII

12.00%

Held by 13 DIIs

Promoter

55.80%

Why is Yatharth Hospital & Trauma Care Services Ltd falling/rising?

11-Jun-2026

As of 10-Jun, Yatharth Hospital & Trauma Care Services Ltd's stock price is currently at 830.95, reflecting a recent decline of 0.92% after three days of gains. Despite this short-term drop, the stock has strong long-term performance, with a year-to-date increase of 21.92% and a 56.69% rise over the past year, supported by solid fundamentals and increased investor interest.

As of 10-Jun, Yatharth Hospital & Trauma Care Services Ltd is experiencing a decline in its stock price, currently at 830.95, which reflects a change of -7.75 (-0.92%). This drop follows a trend reversal after three consecutive days of gains. Despite this recent decline, the stock has shown strong performance over the longer term, with a year-to-date increase of 21.92% and a remarkable 56.69% rise over the past year, significantly outperforming the broader market, which has seen negative returns.<BR><BR>The stock's current performance is in line with sector trends, and it is trading above its moving averages across various time frames, indicating overall strength. Additionally, there has been a notable increase in investor participation, with delivery volume rising by 66.31% compared to the five-day average, suggesting continued interest from investors.<BR><BR>The company's fundamentals remain strong, being net-debt free and demonstrating healthy long-term growth with net sales increasing at an annual rate of 32.09%. Furthermore, the company has reported positive results for the last 11 consecutive quarters, including a record PBDIT and a significant growth in net sales. These factors contribute to a generally favorable outlook for the stock, despite the recent price decline.

View full answer

What does Yatharth Hospit. do?

11-Jun-2026

Yatharth Hospital & Trauma Care Services Ltd is a small-cap company in the hospital industry, recently reporting net sales of ₹342 Cr and a net profit of ₹48 Cr for March 2026. It was incorporated in 2008 and became a public company in 2021, with a market cap of ₹8,054 Cr.

Overview: <BR>Yatharth Hospital & Trauma Care Services Ltd operates in the hospital industry and is categorized as a small-cap company.<BR><BR>History: <BR>The company was incorporated as a Private Limited Company in Delhi on February 28, 2008. It converted its status to a Public Company on November 3, 2021, and changed its name to Yatharth Hospital & Trauma Care Services Limited on November 18, 2021. The most recent quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 342 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 48 Cr (Quarterly Results - Mar 2026) <BR>Market cap: INR 8,054 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 46.00 <BR>Industry P/E: 60 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.00 <BR>Return on Equity: 9.89% <BR>Price to Book: 4.55<BR><BR>Contact Details: <BR>No Company Details Available <BR>Registrar Address: Not available.

View full answer

How big is Yatharth Hospit.?

11-Jun-2026

As of 10th June, Yatharth Hospital & Trauma Care Services Ltd has a market capitalization of 8,054.00 Cr and reported net sales of 1,199.22 Cr and net profit of 176.15 Cr over the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Yatharth Hospital & Trauma Care Services Ltd has a market capitalization of 8,054.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 1,199.22 Cr, while the sum of Net Profit for the same period is 176.15 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds stand at 1,605.46 Cr, and Total Assets are valued at 1,713.06 Cr.

View full answer

Should I buy, sell or hold Yatharth Hospital & Trauma Care Services Ltd?

27-May-2026

Are Yatharth Hospital & Trauma Care Services Ltd latest results good or bad?

26-May-2026

Yatharth Hospital & Trauma Care Services Ltd's latest results show strong revenue growth with Q4 FY26 revenues up 47.36% year-on-year, but declining PAT margins to 13.09% raise concerns about sustainability. Overall, the results are mixed, indicating robust growth alongside operational challenges.

Yatharth Hospital & Trauma Care Services Ltd's latest results present a mixed picture. On one hand, the company has shown impressive revenue growth, with Q4 FY26 revenues reaching ₹341.56 crores, marking a 6.58% increase quarter-on-quarter and a remarkable 47.36% increase year-on-year. The net profit for the same quarter was ₹47.52 crores, reflecting a 4.79% rise from the previous quarter and a 22.73% increase year-on-year.<BR><BR>However, there are concerns regarding margin pressures. The PAT margin has declined to 13.09%, down from 16.71% in Q4 FY25, indicating a significant compression of 362 basis points. This decline in profitability metrics raises questions about the sustainability of the company's growth, especially as it continues to expand aggressively.<BR><BR>Overall, while the revenue and profit figures are strong and indicate robust growth, the declining margins suggest that the company is facing operational challenges that investors should monitor closely.

View full answer

When is the next results date for Yatharth Hospital & Trauma Care Services Ltd?

19-May-2026

The next results date for Yatharth Hospital & Trauma Care Services Ltd is 25 May 2026.

The next results date for Yatharth Hospital & Trauma Care Services Ltd is scheduled for 25 May 2026.

View full answer

How has been the historical performance of Yatharth Hospit.?

15-Nov-2025

Yatharth Hospital has shown significant growth from March 2022 to March 2025, with net sales increasing from 400.94 crore to 880.49 crore, and profit after tax rising from 44.16 crore to 130.55 crore, alongside a substantial improvement in total assets and cash flow. Overall, the hospital has demonstrated robust revenue and profitability growth during this period.

Answer:<BR>The historical performance of Yatharth Hospital shows significant growth in various financial metrics over the past few years.<BR><BR>Breakdown:<BR>Yatharth Hospital's net sales have increased from 400.94 crore in March 2022 to 880.49 crore in March 2025, reflecting a strong upward trend. Total operating income has followed a similar trajectory, rising from 400.94 crore in March 2022 to 880.49 crore in March 2025. The total expenditure, excluding depreciation, also grew from 290.13 crore in March 2022 to 660.30 crore in March 2025, indicating increased operational costs. Operating profit (PBDIT) has seen a notable increase, climbing from 110.81 crore in March 2022 to 236.37 crore in March 2025. Profit before tax rose from 63.11 crore in March 2022 to 171.74 crore in March 2025, while profit after tax increased from 44.16 crore to 130.55 crore in the same period. The company's total assets have surged from 420.57 crore in March 2022 to 1,713.06 crore in March 2025, with total liabilities also rising from 420.57 crore to 1,713.06 crore. Cash flow from operating activities improved significantly, moving from 59 crore in March 2022 to 149 crore in March 2025, contributing to a net cash inflow of 248 crore in March 2025, up from 6 crore in March 2022. Overall, Yatharth Hospital has demonstrated robust growth in revenue, profitability, and asset base over the past few years.

View full answer

Is Yatharth Hospit. technically bullish or bearish?

04-Nov-2025

As of November 3, 2025, Yatharth Hospital's technical trend is mildly bullish, supported by a bullish MACD and moving averages, though caution is advised due to a mildly bearish KST and lack of momentum in the RSI.

As of 3 November 2025, the technical trend for Yatharth Hospital has changed from bullish to mildly bullish. The weekly MACD remains bullish, supported by bullish signals from the Bollinger Bands on both weekly and monthly time frames. The daily moving averages also indicate a bullish stance. However, the KST on a weekly basis is mildly bearish, suggesting some caution. The RSI shows no signal on both weekly and monthly charts, indicating a lack of momentum. Overall, the current technical stance is mildly bullish, driven primarily by the bullish MACD and moving averages, despite some mixed signals from other indicators.

View full answer

Is Yatharth Hospit. overvalued or undervalued?

09-Oct-2025

As of October 8, 2025, Yatharth Hospital is considered very expensive and overvalued, with a PE ratio of 56.35, an EV to EBITDA of 32.50, and a Price to Book Value of 4.99, despite having a lower PE ratio than peers like Max Healthcare and Fortis Healthcare, while significantly outperforming the Sensex with a year-to-date return of 46.93%.

As of 8 October 2025, the valuation grade for Yatharth Hospital has moved from expensive to very expensive, indicating a significant increase in perceived valuation. The company is currently considered overvalued. Key ratios include a PE ratio of 56.35, an EV to EBITDA of 32.50, and a Price to Book Value of 4.99, all of which suggest a high valuation relative to earnings and book value.<BR><BR>In comparison to its peers, Yatharth Hospital's PE ratio is lower than that of Max Healthcare at 92.31 and Fortis Healthcare at 86.26, both of which are also categorized as very expensive. However, it is notably higher than Narayana Hrudaya, which has a PE of 46.14 and is classified as expensive. The recent stock performance has outpaced the Sensex, with a year-to-date return of 46.93% compared to the Sensex's 4.65%, reinforcing the notion that the stock is currently overvalued in the market.

View full answer

Who are the top shareholders of the Yatharth Hospit.?

17-Jul-2025

The top shareholders of Yatharth Hospital include promoter Ajay Kumar Tyagi with 30.59%, mutual funds holding 9.42%, foreign institutional investors at 4.45%, and individual investors with 14.87%. The largest public shareholder is Kotak Mahindra Trustee Co Ltd, representing the Kotak Multicap Fund, with 4.36%.

The top shareholders of Yatharth Hospital include the promoters, who hold the majority of the shares. The promoter with the highest holding is Ajay Kumar Tyagi, with a significant stake of 30.59%. Additionally, mutual funds hold 9.42% of the shares through 8 schemes, while foreign institutional investors (FIIs) account for 4.45% with 30 different FIIs involved. The highest public shareholder is Kotak Mahindra Trustee Co Ltd, representing the Kotak Multicap Fund, which holds 4.36%. Individual investors collectively hold 14.87% of the company's shares.

View full answer

Who are the peers of the Yatharth Hospit.?

16-Jul-2025

Yatharth Hospital's peers include Dr Agarwal's Healthcare, Jupiter Life Line, Health.Global, Kovai Medical, Indraprastha Medical, Artemis Medicare, Shalby, Dr Agarwal's Eye, GPT Healthcare, and Jeena Sikho. In terms of performance, Indraprastha Medical leads with a 1-year return of 99.54%, while Yatharth Hospital has a return of 38.67%.

Peers: The peers of Yatharth Hospit. are Dr Agarwal's Hea, Jupiter Life Lin, Health.Global, Kovai Medical, Indrapr.Medical, Artemis Medicare, Shalby, Dr Agarwal's Eye, GPT Healthcare, and Jeena Sikho.<BR><BR>Quality Snapshot: Excellent management risk is observed at Jupiter Life Lin, Indrapr.Medical, and GPT Healthcare, while Good management risk is found at Dr Agarwal's Hea, Kovai Medical, and the rest. Average management risk is noted at Yatharth Hospit., Shalby, and Dr Agarwal's Eye, while Below Average management risk is seen at Health.Global and Artemis Medicare. For Growth, Excellent growth is observed at Jeena Sikho, while Good growth is found at Dr Agarwal's Hea, Yatharth Hospit., Kovai Medical, and Indrapr.Medical, and the rest. Average growth is noted at Dr Agarwal's Eye and the rest, while Below Average growth is seen at Jupiter Life Lin, Health.Global, Artemis Medicare, and Shalby. In terms of Capital Structure, Excellent capital structure is observed at Jupiter Life Lin, Indrapr.Medical, and GPT Healthcare, while Good capital structure is found at Dr Agarwal's Hea, Kovai Medical, and Shalby, and the rest. Average capital structure is noted at Artemis Medicare, while Below Average capital structure is seen at Health.Global.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Indrapr.Medical at 99.54%, while the peer with the lowest 1-year return is Shalby at -33.71%. Yatharth Hospit.'s 1-year return is 38.67%, which is significantly lower than Indrapr.Medical's but higher than Shalby's. Additionally, the peers with negative six-month returns include Artemis Medicare and Shalby.

View full answer

Who are in the management team of Yatharth Hospit.?

16-Jul-2025

As of March 2022, the management team of Yatharth Hospital includes Ajay Kumar Tyagi (Chairman & Wholetime Director), Kapil Kumar (Managing Director), Yatharth Tyagi (Whole-time Director), Mukesh Sharma, Sanjeev Upadhyaya, and Promila Bhardwaj (Independent Directors), and Ritesh Mishra (Company Secretary & Compliance Officer). Each member contributes to the company's governance and operations.

As of March 2022, the management team of Yatharth Hospital includes the following members:<BR><BR>1. Ajay Kumar Tyagi - Chairman & Wholetime Director<BR>2. Kapil Kumar - Managing Director<BR>3. Yatharth Tyagi - Whole-time Director<BR>4. Mukesh Sharma - Independent Director<BR>5. Sanjeev Upadhyaya - Independent Director<BR>6. Ritesh Mishra - Company Secretary & Compliance Officer<BR>7. Promila Bhardwaj - Independent Director<BR><BR>Each member plays a crucial role in the governance and operational management of the company.

View full answer

Has Yatharth Hospit. declared dividend?

06-Jun-2025

No Dividend History Available

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Poor Management Efficiency with a low ROE of 9.01%

  • The company has been able to generate a Return on Equity (avg) of 9.01% signifying low profitability per unit of shareholders funds
2

The company is Net-Debt Free

 
3

Healthy long term growth as Net Sales has grown by an annual rate of 32.09%

 
4

The company has declared Positive results for the last 11 consecutive quarters

5

With ROE of 9.9, it has a Expensive valuation with a 4.5 Price to Book Value

6

Majority shareholders : Promoters

 
7

Market Beating Performance

stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

Hospital

stock-summary
Market cap

INR 7,995 Cr (Small Cap)

stock-summary
P/E

46.00

stock-summary
Industry P/E

60

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.00

stock-summary
Return on Equity

9.89%

stock-summary
Price to Book

4.51

Revenue and Profits:
Net Sales:
342 Cr
(Quarterly Results - Mar 2026)
Net Profit:
48 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
18.69%
0%
18.69%
6 Months
19.4%
0%
19.4%
1 Year
56.52%
0%
56.52%
2 Years
99.38%
0%
99.38%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Yatharth Hospit. for the last several years.

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
32.09%
EBIT Growth (5y)
22.50%
EBIT to Interest (avg)
18.14
Debt to EBITDA (avg)
0.35
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0.65
Tax Ratio
23.13%
Dividend Payout Ratio
0
Pledged Shares
10.73%
Institutional Holding
17.26%
ROCE (avg)
17.68%
ROE (avg)
9.01%

Valuation key factors

Factor
Value
P/E Ratio
46
Industry P/E
60
Price to Book Value
4.51
EV to EBIT
41.11
EV to EBITDA
28.36
EV to Capital Employed
4.51
EV to Sales
6.70
PEG Ratio
1.30
Dividend Yield
NA
ROCE (Latest)
10.97%
ROE (Latest)
9.89%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bearish
Dow Theory
Mildly Bearish
Bullish
OBV
Mildly Bearish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2026stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

10.7343

Mutual Funds

Held by 7 Schemes (9.37%)

FIIs

Held by 58 FIIs (5.25%)

Promoter with highest holding

Ajay Kumar Tyagi (30.59%)

Highest Public shareholder

Kotak Mahindra Trustee Co Ltd A/c Kotak Multicap Fund (4.89%)

Individual Investors Holdings

20.47%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 6.58% vs 14.69% in Dec 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 4.79% vs 9.97% in Dec 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "341.56",
          "val2": "320.47",
          "chgp": "6.58%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "79.91",
          "val2": "74.25",
          "chgp": "7.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "5.07",
          "val2": "1.02",
          "chgp": "397.06%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "47.52",
          "val2": "45.35",
          "chgp": "4.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "23.40%",
          "val2": "23.17%",
          "chgp": "0.23%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Consolidated) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is 25.06% vs 31.85% in Sep 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is 35.77% vs 31.52% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "537.19",
          "val2": "429.55",
          "chgp": "25.06%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "129.01",
          "val2": "108.30",
          "chgp": "19.12%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.45",
          "val2": "4.48",
          "chgp": "-89.96%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "83.28",
          "val2": "61.34",
          "chgp": "35.77%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "24.02%",
          "val2": "25.21%",
          "chgp": "-1.19%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is 32.21% vs 31.70% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is 40.07% vs 20.62% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "857.66",
          "val2": "648.71",
          "chgp": "32.21%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "203.26",
          "val2": "163.22",
          "chgp": "24.53%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.47",
          "val2": "6.54",
          "chgp": "-77.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "128.63",
          "val2": "91.83",
          "chgp": "40.07%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "23.70%",
          "val2": "25.16%",
          "chgp": "-1.46%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2026 is 37.10% vs 31.31% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2026 is 34.34% vs 14.04% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,207.17",
          "val2": "880.49",
          "chgp": "37.10%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "292.12",
          "val2": "220.19",
          "chgp": "32.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "6.54",
          "val2": "7.51",
          "chgp": "-12.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "175.38",
          "val2": "130.55",
          "chgp": "34.34%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "24.20%",
          "val2": "25.01%",
          "chgp": "-0.81%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQstock-summary

Mar'26
Dec'25
Change(%)
Net Sales
341.56
320.47
6.58%
Operating Profit (PBDIT) excl Other Income
79.91
74.25
7.62%
Interest
5.07
1.02
397.06%
Exceptional Items
0.00
0.00
Consolidate Net Profit
47.52
45.35
4.79%
Operating Profit Margin (Excl OI)
23.40%
23.17%
0.23%
Values in Rs Cr.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Mar 2026 is 6.58% vs 14.69% in Dec 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Mar 2026 is 4.79% vs 9.97% in Dec 2025

Half Yearly Results Snapshot (Consolidated) - Sep'25stock-summary

Sep'25
Sep'24
Change(%)
Net Sales
537.19
429.55
25.06%
Operating Profit (PBDIT) excl Other Income
129.01
108.30
19.12%
Interest
0.45
4.48
-89.96%
Exceptional Items
0.00
0.00
Consolidate Net Profit
83.28
61.34
35.77%
Operating Profit Margin (Excl OI)
24.02%
25.21%
-1.19%
Values in Rs Cr.
Direction Arrows
Net Sales

Growth in half year ended Sep 2025 is 25.06% vs 31.85% in Sep 2024

Direction Arrows
Consolidated Net Profit

Growth in half year ended Sep 2025 is 35.77% vs 31.52% in Sep 2024

Nine Monthly Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
857.66
648.71
32.21%
Operating Profit (PBDIT) excl Other Income
203.26
163.22
24.53%
Interest
1.47
6.54
-77.52%
Exceptional Items
0.00
0.00
Consolidate Net Profit
128.63
91.83
40.07%
Operating Profit Margin (Excl OI)
23.70%
25.16%
-1.46%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2025 is 32.21% vs 31.70% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in nine months ended Dec 2025 is 40.07% vs 20.62% in Dec 2024

Annual Results Snapshot (Consolidated) - Mar'26stock-summary

Mar'26
Mar'25
Change(%)
Net Sales
1,207.17
880.49
37.10%
Operating Profit (PBDIT) excl Other Income
292.12
220.19
32.67%
Interest
6.54
7.51
-12.92%
Exceptional Items
0.00
0.00
Consolidate Net Profit
175.38
130.55
34.34%
Operating Profit Margin (Excl OI)
24.20%
25.01%
-0.81%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2026 is 37.10% vs 31.31% in Mar 2025

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2026 is 34.34% vs 14.04% in Mar 2025

stock-summaryCompany CV
About Yatharth Hospital & Trauma Care Services Ltd stock-summary
stock-summary
Yatharth Hospital & Trauma Care Services Ltd
Small Cap
Hospital
Yatharth Hospital & Trauma Care Services Limited was formerly incorporated as a Private Limited Company in Delhi dated February 28, 2008. On November 3, 2021, the status converted into a Public Company and name of the Company was changed to `Yatharth Hospital & Trauma Care Services Limited' on November 18, 2021 issued by the RoC.
Company Coordinates stock-summary
Icon
No Company Details Available